[Suppression of multiple myeloma tumor growth in vivo by transfection of platelet factor 4 or 17-70 cDNA].

This study was purposed to investigate the effects of viral vector-mediated gene transfer of platelet factor 4 (PF4) or 17-70 cDNA on cell growth of multiple myeloma (MM) in vivo. Full length and p17-70 cDNA of PF4 were cloned into virapower system to transfect packing cell line 293 and produce lentiviral vectors. 3 multiple myeloma cell lines were transferred platelet factor 4 or 17-70 cDNA by lentiviral vectors.

[The ultrastructure study of membrane surface of the bone marrow CD34+ cells with the atomic force microscope].

Human CD34(+) hematopoietic cells, a distinctive cell population containing hematopoietic stem/progenitor cells (HSPC), have the capability to highly self-renewal, differentiation into all lineages of committed progenitor cells and reconstitution of both long-term hematopoiesis and immunefunctions after transplantation. CD34(+) hematopoietic cells from bone marrow (BM) recently have been employed for treating neoplastic and genetic disorders. This study was aimed to investigate membrane surface ultrastructures of bone marrow CD34(+) cell from mormal persons and leukemia patients and to compare their morphologic differences by using atomic force microscope (AFM).

[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].

Background & Objective: The hematological complete remission (CR) rate of the FLAG regimen [fludarabine and cytarabine (Ara-C) and granulocyte-colony stimulating factor] for relapsed and refractory acute non- lymphocytic leukemia (ANLL) was 50-64%. The aim of this study was to investigate the modified FLAG regimen (Ara-C reduced to 200 mg per day intravenous injection for 5 to 7 days, and the patients were not administrated G-CSF before fludarabine and Ara-C) to examine whether it can achieve the same effectiveness and minor side effects.

Methods: Of 33 patients with acute leukemia, there were 16 cases with ANLL, 12 cases with refractory acute lymphocytic leukemia (ALL) and 5 cases with relapsed ALL, respectively.

[Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].

Objective: To study the possibility of curing chronic myeloid leukemia with autogeneic hemopoietic stem cell transplantation in patients with negative Philadelphia (Ph) chromosome induced by imatinib mesylate (STI 571) treatment.

Methods: Two patients with chronic myeloid leukemia in chronic phase, who had 90% Ph chromosome-positive cells and bcr/abl fusion gene-positive cells as shown by interphase fluorescence in situ hybridization (I-FISH), failed to respond favorably to interferon-alpha therapy in the treatment courses of 7 and 8 months, respectively. Treatment with STI 571 at a daily dose of 300 to 400 mg for 5 months to 8 months was subsequently implemented, after which the Ph chromosome and bcr/abl fusion genes became normal in detection for 3 times.

[Surface morphology of CD34+ cells under atomic force microscope].

Objective: To observe the difference in surface morphology and structure between CD34(+) cells from normal human subjects and from patients with leukemia.

Methods: Bone marrow mononuclear cells from 3 normal human subjects and 3 patients with M2b leukemia were collected by Percoll gradient centrifugation, followed by purification of CD34(+) cells by means of immunomagnetic bead separation (MiniMAC) and examination with flow cytometry. The morphology of the cells were then observed with optical and atomic force microscope (AFM) in air.

[Modified FLAG regimen in the management of refractory acute myeloid leukemia].

Objective: To evaluate the therapeutic effect of modified FLAG regimen in the management of refractory acute myeloid leukemia (AML).

Methods: Sixteen patients with refractory AML were divided into two groups. In modified FLAG regimen group (n=10), the patients received fludarabine (Flu, 50 mg/d, VDx5 d) and Ara-c (200 mg/d, VDx5 or 7 d).